Photo by Edward Jenner via Pexels
It is driven by the rising digital adoption in pharmaceutical and biotech research.
According to ResearchAndMarkets.com, the decentralized clinical trials (DCTS) market is expected to grow from 9.63B in 2024 to $21.34B in 2030, with a CAGR of 14.16%.
This growth is driven by the pharmaceutical and biotech industries that employ digital solutions such as wearable devices, telemedicine and mobile applications for remote patient monitoring and data collection.
The rising demand for faster drug development and cost-effective trial solutions makes DCT an attractive alternative to traditional models. These trials greatly reduce hiring schedules and operating expenses, thereby improving the process.
In addition, advances in digital health technologies and telehealth can improve trial logistics, ensuring wider patient participation and realistic evidence collection.
Despite its advantages, DCTs still face challenges, especially in regulatory compliance and data security. Existing regulations are often tailored to traditional experimental models and need to be adapted to accommodate digital and remote approaches.
Furthermore, as cyber threats become more common, people pose risks to patient privacy and the security of electronic health records.
Join the Healthcare Asia Magazine Community
Since you're here…
…You can promote your company with us and connect with your customers in a variety of ways. Our team can help you Dight and create advertising campaigns on print and digitally on this website and on print magazines.
We can also organize real-life or digital events for you and find thought leader speakers and industry leaders who can become your potential partners to attend. We also run a number of award programs that give you the opportunity to earn your achievements this year, and you can join as a participant or sponsor.
Let us help you move your business forward with a good partnership!
